Symbiosis Group
5
67M
5
2
- Areas of investment
Summary
Among the most popular portfolio startups of the fund, we may highlight Vedanta Biosciences, Spinifex Pharmaceuticals. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Medical.
The high activity for fund was in 2019. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The higher amount of exits for fund were in 2015.
The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Symbiosis Group, startups are often financed by Seventure Partners, Rock Springs Capital, PureTech Health. The meaningful sponsors for the fund in investment in the same round are Uniseed Ventures, Shumway Capital, Partners Investment. In the next rounds fund is usually obtained by Uniseed Ventures, GBS Ventures, Brandon Capital Partners.
Investments analytics
Analytics
- Total investments
- 5
- Lead investments
- 0
- Exits
- 2
- Investments by industry
- Biotechnology (5)
- Health Care (2)
- Business Development (1)
- Medical (1)
- Drug Discovery (1) Show 10 more
- Investments by region
-
- United States (4)
- United Kingdom (1)
- Peak activity year
- 2019
- Number of Unicorns
- 1
- Number of Decacorns
- 2
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Avg. valuation at time of investment
- 2B
- Group Appearance index
- 1.00
- Avg. company exit year
- 10
- Avg. multiplicator
- 3.01
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Vedanta Biosciences | 13 May 2019 | Biotechnology, Drug Discovery, Medical, Business Development | Late Stage Venture | 18M | United States, Cambridge, Massachusetts |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.